FAK/SRC-JNK axis promotes ferroptosis via upregulating ACSL4 expression - PubMed
4 hours ago
- #FAK/SRC-JNK
- #ACSL4
- #ferroptosis
- FAK/SRC-JNK axis promotes ferroptosis by upregulating ACSL4 expression.
- Defactinib, a FAK inhibitor, is identified as a novel ferroptosis suppressor.
- JNK downstream transcription factors (ATF2, NFATC1, NFATC3, SMAD4) promote ferroptosis by activating ACSL4 expression.
- Other JNK-associated transcription factors (c-Jun, STAT3, ELK1, HSF1) inhibit ferroptosis by repressing ACSL4 expression.
- Elevated FAK/SRC-JNK signaling sensitizes cancer cells to ferroptosis-inducing therapies.
- Inhibition of FAK/SRC-JNK pathway protects against acute pancreatitis by suppressing ferroptosis.
- The study highlights therapeutic potential of targeting FAK/SRC-JNK mediated ferroptosis for cancer and acute pancreatitis treatment.